New research on semaglutide coadministered with cagrilintide for adults with overweight or obesity was published on 2025-01-01. This pivotal publication details findings from a study investigating the combination's potential for weight management.
Background
Semaglutide, known by brand names such as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for the treatment of type 2 diabetes and, at higher doses (as Wegovy), for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. This publication explores its coadministration with cagrilintide, another investigational agent, in the context of weight loss for individuals with overweight or obesity.
Trial design
The published research, referred to as REDEFINE 1, investigated the coadministration of cagrilintide and semaglutide. The study focused on adults diagnosed with overweight or obesity, aiming to assess the combination's effectiveness in achieving weight loss. The trial's objective was to see how well the combination, referred to as CagriSema, helps people with excess body weight lose weight.
What this means
The publication of these findings provides new insights into the potential of combining semaglutide with cagrilintide for weight management. While specific outcome measurements are not detailed in the available information, the study's focus on adults with overweight or obesity suggests an ongoing effort to develop more effective therapeutic strategies for this condition. The results contribute to the growing body of evidence surrounding combination therapies in metabolic health.
Source
The information regarding the coadministration of cagrilintide and semaglutide was published in a pivotal article on 2025-01-01. The source is PubMed, an authoritative database for biomedical literature, and the publication can be accessed via pubmed.ncbi.nlm.nih.gov.